



**Innovative Biosensors, Inc.
Invited to Present at
Mid-Atlantic Bio and MAC Alliance Conferences**

Rockville, MD, October 18, 2007 – Innovative Biosensors, Inc. (IBI), a company developing rapid, ultra-sensitive tests to detect harmful pathogens for both the clinical infectious disease and biodefense markets, today announced that Joe Hernandez, President and Chief Executive Officer, has been invited to present at the MAC Alliance Conference on October 23-24 at the Philadelphia Marriott, as well as the 2007 Mid-Atlantic Bio Conference on October 24-26 at the North Marriott Conference Center in Bethesda, MD.

The MAC Alliance Venture Conference (MAVC) is the oldest, most established venture gathering in the Northeast region and has been the catalyst for billions of dollars in venture funding and entrepreneurial success in the region.

The 2007 Mid-Atlantic Bio Conference, a regionally supported bioscience industry convention, is co-hosted by the Mid-Atlantic Venture Association, the Virginia Biotechnology Association, and MdBio/Tech Council of Maryland.

“These regional meetings offer us the opportunity to share with the investment community the progress we have made in our core markets” said Joe Hernandez. “We look forward to adding value to the agenda of these well attended venture meetings.”

About Innovative Biosensors, Inc.

Innovative Biosensors, Inc. is a privately held company developing novel technologies for the rapid detection of pathogens in biodefense applications and human clinical diagnostics. IBI’s technology has been tailored to rapidly and sensitively detect biological threats in building security, military, and civil defense applications. Additionally, the technology platform is being used to develop rapid tests for the detection of hospital-acquired infections. Additional information is available at www.innovativebiosensors.com.

This release may contain forward-looking statements that are subject to certain risks and uncertainties, including Innovative Biosensors, Inc.’s mission to develop and commercialize instrument systems, Innovative Biosensors, Inc.’s ability to develop new technologies to conduct rapid diagnosis. Such statements are based on management’s current expectations and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Innovative Biosensors, Inc. cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following:

Innovative Biosensors, Inc.'s expectations that they will incur operating losses in the near future, the early stage of preclinical and clinical testing and trials, uncertainties surrounding the availability of additional funding, Innovative Biosensors, Inc.'s reliance on research collaborations, the actions of competitors and the development of competing technologies, potential patent infringement claims against Innovative Biosensors, Inc.'s products, processes and technologies, Innovative Biosensors, Inc.'s ability to protect their patents and proprietary rights and uncertainties relating to commercialization rights.

Contact:

Joe Hernandez

President and CEO

Innovative Biosensors, Inc.

Phone: 301.517.0324

www.innovativebiosensors.com

info@innovativebiosensors.com